Shigella sonnei Vaccines

Creative Biolabs has extensive research experience in the field of bacterial vaccines, especially in the Shigella genus. We have conducted extensive and in-depth research, and have a thorough understanding of the pathogenic mechanism of bacteria and its interaction with the host. Thus, we have developed a series of related products independently, and also established a reliable vaccine service system. We believe that with our joint efforts, your vaccine development path will be unimpeded!

Shigella sonnei

Shigella sonnei is a type of Shigella that, together with Shigella flexneri, is the causative agent of 90% of Shigellosis. S. sonnei has the same O antigen as the other lipopolysaccharides of Shigella. This antigen is the main molecule on the surface of Shigella as the target for adaptive immunity of the host responding to Shigella infection. These surface structures have cross-reactivity, and vaccines based on O-antigen have good effects in preventing infection of humans by S. sonnei. The O-antigen gene is located in the invasion plasmid of S. sonnei, which is essential for the entry of bacteria into epithelial cells. The identified S. sonnei has four lineages, and lineage III is the most widely spread and has become the main strain in Africa, Asia, and South America. Lineage III's S. sonnei contains a class II integron that provides resistance to streptomycin, trimethoprim.

Development of the Shigella sonnei Vaccines

There are currently two approaches to the development of Shigella's cellular vaccines, based on virG mutations and guaBA-based mutations, since virG is involved in the spread of bacteria in epithelial cells, whereas guaBA is involved in bacterial replication. In addition, studies have been conducted to delete sen and set genes associated with bacterial enterotoxin. A vaccine candidate for S. sonnei, WRSs1, is based on the VirG mutation, which is currently undergoing clinical trials in infants and young children. The formalin-inactivated trivalent whole-cell vaccine containing S. sonnei, S. flexneri 2a and 3a is protective in animal studies and is currently undergoing clinical evaluation. Another study of polyvalent heat-inactivated vaccines containing S. sonnei, S. flexneri 2a, S. flexneri 3a, S. flexneri 6, and S. dysenteriae in guinea pig models also showed immunogenicity and protection against challenges by different virus strains. Mutations to delete immune-determined Ipa and O antigen-prepared vaccines are not only highly attenuated, but also able to stimulate the protection against challenges by heterologous bacteria in mouse models. The vaccine GMMA, which targets the S. sonnei outer membrane vesicles without O-SP/Lipis A, can protect animals from S. flexneriin and S. sonnei after three intranasal immunizations. These vaccines are currently undergoing clinical trials. IpaB and IpaD are important components of the type III secretion apparatus (TTSA) and make it functional. And they are a common component of Shigella spp and therefore can be used as a target for the universal Shigella vaccine. IpaB and IpaD-based subunit vaccines exhibit good immunogenicity and protective effects in mouse models, while also stimulating strong systemic and mucosal antibodies and cellular immune responses.

Creative Biolabs' leading position in the vaccine industry comes from its consistent enthusiasm for years of research and devoted attitude to its customers. In order to provide the highest quality service to our customers with the highest professional ability, we are constantly learning and exploring, and continually absorbing the most advanced theories and technologies in the world, combined with our innovative ability, we have successfully developed a series of high-quality products and services. We are proud that our products and services have helped researchers around the world complete their vaccine development. If you have any problems with vaccine research, please give us the opportunity to serve you!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.